SMO and metabolic dysfunction-associated steatotic liver disease: We reported previously that the severity of fibrosing steatohepatitis parallels hepatic expression of the senescence markers p16, p21, and β-gal activity in people with MASLD (15, 16), and all of these markers were increased by deleting Smo in mouse hepatocytes during CDA-HFD exposure (Figure 1, D–F).